{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T12:36:25Z","timestamp":1788957385810,"version":"build-2803163510"},"reference-count":141,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,8,26]],"date-time":"2022-08-26T00:00:00Z","timestamp":1661472000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>It is urgently needed to update the comprehensive analysis about the efficacy or effectiveness of COVID-19 vaccines especially during the COVID-19 pandemic caused by SARS-CoV-2 Delta and Omicron variants. In general, the current COVID-19 vaccines showed a cumulative efficacy of 66.4%, 79.7%, and 93.6% to prevent SARS-CoV-2 infection, symptomatic COVID-19, and severe COVID-19, respectively, but could not prevent the asymptomatic infection of SARS-CoV-2. Furthermore, the current COVID-19 vaccines could effectively prevent COVID-19 caused by the Delta variant although the incidence of breakthrough infection of the SARS-CoV-2 Delta variant increased when the intervals post full vaccination extended, suggesting the waning effectiveness of COVID-19 vaccines. In addition, one-dose booster immunization showed an effectiveness of 74.5% to prevent COVID-19 caused by the Delta variant. However, current COVID-19 vaccines could not prevent the infection of Omicron sub-lineage BA.1.1.529 and had about 50% effectiveness to prevent COVID-19 caused by Omicron sub-lineage BA.1.1.529. Furthermore, the effectiveness was 87.6% and 90.1% to prevent severe COVID-19 and COVID-19-related death caused by Omicron sub-lineage BA.2, respectively, while one-dose booster immunization could enhance the effectiveness of COVID-19 vaccines to prevent the infection and COVID-19 caused by Omicron sub-lineage BA.1.1.529 and sub-lineage BA.2. Two-dose booster immunization showed an increased effectiveness of 81.8% against severe COVID-19 caused by the Omicron sub-lineage BA.1.1.529 variant compared with one-dose booster immunization. The effectiveness of the booster immunization with RNA-based vaccine BNT162b2 or mRNA-1273 was over 75% against severe COVID-19 more than 17 weeks after booster immunization whereas the heterogenous booster immunization showed better effectiveness than homologous booster immunization. In summary, the current COVID-19 vaccines could effectively protect COVID-19 caused by Delta and Omicron variants but was less effective against Omicron variant infection. One-dose booster immunization could enhance protection capability, and two-dose booster immunization could provide additional protection against severe COVID-19.<\/jats:p>","DOI":"10.3389\/fimmu.2022.945930","type":"journal-article","created":{"date-parts":[[2022,8,26]],"date-time":"2022-08-26T07:30:42Z","timestamp":1661499042000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":28,"title":["A comprehensive analysis of the efficacy and effectiveness of COVID-19 vaccines"],"prefix":"10.3389","volume":"13","author":[{"given":"Xiaofeng","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiao","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu\u2019nan","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shixing","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,8,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41579-020-00459-7","article-title":"Characteristics of SARS-CoV-2 and COVID-19","volume":"19","author":"Hu","year":"2021","journal-title":"Nat Rev Microbiol"},{"key":"B2","volume-title":"Draft landscape and tracker of COVID-19 candidate vaccines","year":"2022"},{"key":"B3","volume-title":"WHO coronavirus (COVID-19) dashboard","year":"2022"},{"key":"B4","volume-title":"Coronavirus disease (COVID-19) SARS-CoV-2-variants","year":"2022"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.mtbio.2022.100265","article-title":"Adsorption of SARS CoV-2 spike proteins on various functionalized surfaces correlates with the high transmissibility of delta and omicron variants","volume":"14","author":"Dobrynin","year":"2022","journal-title":"Mater Today Bio"},{"key":"B6","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s43556-022-00074-3","article-title":"Omicron-included mutation-induced changes in epitopes of SARS-CoV-2 spike protein and effectiveness assessments of current antibodies","volume":"3","author":"Guo","year":"2022","journal-title":"Mol BioMed"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms10020280","article-title":"Prion-like domains in spike protein of SARS-CoV-2 differ across its variants and enable changes in affinity to ACE2","volume":"10","author":"Tetz","year":"2022","journal-title":"Microorganisms"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2021.08.001","article-title":"A comprehensive analysis of the efficacy and safety of COVID-19 vaccines","volume":"29","author":"Cai","year":"2021","journal-title":"Mol Ther"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9040341","article-title":"Factors influencing the efficacy of COVID-19 vaccines: A quantitative synthesis of phase III trials","volume":"9","author":"Calzetta","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.714170","article-title":"Efficacy, immunogenicity and safety of COVID-19 vaccines: A systematic review and meta-analysis","volume":"12","author":"Sharif","year":"2021","journal-title":"Front Immunol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9060582","article-title":"Efficacy and safety of COVID-19 vaccines in phase III trials: A meta-analysis","volume":"9","author":"Cheng","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3126\/nje.v11i1.36163","article-title":"Development and implementation of a potential coronavirus disease 2019 (COVID-19) vaccine: A systematic review and meta-analysis of vaccine clinical trials","volume":"11","author":"Sathian","year":"2021","journal-title":"Nepal J Epidemiol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2021.26.28.2100563","article-title":"Efficacy and effectiveness of COVID-19 vaccines against SARS-CoV-2 infection: interim results of a living systematic review","volume":"26","author":"Harder","year":"2021","journal-title":"Euro Surveill"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2021.26.41.2100920","article-title":"Effectiveness of COVID-19 vaccines against SARS-CoV-2 infection with the delta (B.1.617.2) variant: second interim results of a living systematic review and meta-analysis, 1 January to 25 august 2021","volume":"26","author":"Harder","year":"2021","journal-title":"Euro Surveill"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1101\/2021.09.17.21263549","article-title":"A systematic review of COVID-19 vaccine efficacy and effectiveness against SARS-CoV-2 infection and disease","author":"Higdon","year":"2021","journal-title":"medRxiv"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s10787-021-00839-2","article-title":"Real-world effectiveness of BNT162b2 mRNA vaccine: a meta-analysis of large observational studies","volume":"29","author":"Kow","year":"2021","journal-title":"Inflammopharmacology"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1101\/2021.09.23.21264048","article-title":"Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis","author":"Zeng","year":"2021","journal-title":"medRxiv"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1101\/2021.12.10.21267408","article-title":"Adolescent vaccination with BNT162b2 (Comirnaty, pfizer-BioNTech) vaccine and effectiveness against COVID-19: national test-negative case-control study, England","author":"Powell","year":"2021","journal-title":"medRxiv"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1101\/2022.02.24.22271396","article-title":"Protection by vaccines and previous infection against the omicron variant of SARS-CoV-2","author":"\u0160m\u00edd","year":"2022","journal-title":"medRxiv"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1101\/2022.01.15.22269360","article-title":"Effectiveness of mRNA COVID-19 vaccines against omicron among veterans","author":"Yinong","year":"2022","journal-title":"medRxiv"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01753-y","article-title":"Effectiveness of mRNA-1273 against SARS-CoV-2 omicron and delta variants","volume":"28","author":"Tseng","year":"2022","journal-title":"Nat Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2201821","article-title":"Protection with a third dose of mRNA vaccine against SARS-CoV-2 variants in frontline workers","volume":"386","author":"Yoon","year":"2022","journal-title":"N Engl J Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2021.100150","article-title":"Decreased infectivity following BNT162b2 vaccination: A prospective cohort study in Israel","volume":"7","author":"Regev-Yochay","year":"2021","journal-title":"Lancet Reg Health Eur"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7107e2","article-title":"Waning 2-dose and 3-dose effectiveness of mRNA vaccines against COVID-19-Associated emergency department and urgent care encounters and hospitalizations among adults during periods of delta and omicron variant predominance - VISION network, 10 states, august 2021-January 2022","volume":"71","author":"Ferdinands","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.0470","article-title":"Association between 3 doses of mRNA COVID-19 vaccine and symptomatic infection caused by the SARS-CoV-2 omicron and delta variants","volume":"327","author":"Accorsi","year":"2022","journal-title":"JAMA"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2119451","article-title":"Covid-19 vaccine effectiveness against the omicron (B.1.1.529) variant","volume":"386","author":"Andrews","year":"2022","journal-title":"N Engl J Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1101\/2021.12.30.21268565","article-title":"Effectiveness of COVID-19 vaccines against omicron or delta infection","author":"Buchan","year":"2021","journal-title":"medRxiv"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9111267","article-title":"COVID-19 breakthrough infections and transmission risk: Real-world data analyses from germany's largest public health department (Cologne)","volume":"9","author":"Hsu","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000100","article-title":"The prisma statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: Explanation and elaboration","volume":"6","author":"Liberati","year":"2009","journal-title":"PloS Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2202826","article-title":"BNT162b2 protection against the omicron variant in children and adolescents","volume":"386","author":"Price","year":"2022","journal-title":"N Engl J Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2022.06.005","article-title":"Atlas of currently available human neutralizing antibodies against SARS-CoV-2 and escape by omicron sub-variants BA.1\/BA.1.1\/BA.2\/BA.3","volume":"55","author":"Huang","year":"2022","journal-title":"Immunity"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.8565","article-title":"Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: A randomized clinical trial","volume":"326","author":"Al Kaabi","year":"2021","journal-title":"JAMA"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2113017","article-title":"Efficacy of the mRNA-1273 SARS-CoV-2 vaccine at completion of blinded phase","volume":"385","author":"El Sahly","year":"2021","journal-title":"N Engl J Med"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00432-3","article-title":"Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: A pooled analysis of four randomised trials","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00234-8","article-title":"Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia","volume":"397","author":"Logunov","year":"2021","journal-title":"Lancet"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)02000-6","article-title":"Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial","volume":"398","author":"Ella","year":"2021","journal-title":"Lancet"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2109522","article-title":"Evaluation of mRNA-1273 SARS-CoV-2 vaccine in adolescents","volume":"385","author":"Ali","year":"2021","journal-title":"N Engl J Med"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2105290","article-title":"Phase 3 safety and efficacy of AZD1222 (ChAdOx1 nCoV-19) covid-19 vaccine","volume":"385","author":"Falsey","year":"2021","journal-title":"N Engl J Med"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107456","article-title":"Safety, immunogenicity, and efficacy of the BNT162b2 covid-19 vaccine in adolescents","volume":"385","author":"Frenck","year":"2021","journal-title":"N Engl J Med"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107659","article-title":"Safety and efficacy of NVX-CoV2373 covid-19 vaccine","volume":"385","author":"Heath","year":"2021","journal-title":"N Engl J Med"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2101544","article-title":"Safety and efficacy of single-dose Ad26.COV2.S vaccine against covid-19","volume":"384","author":"Sadoff","year":"2021","journal-title":"N Engl J Med"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01429-X","article-title":"Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey","volume":"398","author":"Tanriover","year":"2021","journal-title":"Lancet"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2110345","article-title":"Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine through 6 months","volume":"385","author":"Thomas","year":"2021","journal-title":"N Engl J Med"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2102214","article-title":"Efficacy of the ChAdOx1 nCoV-19 covid-19 vaccine against the B.1.351 variant","volume":"384","author":"Madhi","year":"2021","journal-title":"N Engl J Med"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2021.09.052","article-title":"A phase III, observer-blind, randomized, placebo-controlled study of the efficacy, safety, and immunogenicity of SARS-CoV-2 inactivated vaccine in healthy adults aged 18-59 years: An interim analysis in Indonesia","volume":"39","author":"Fadlyana","year":"2021","journal-title":"Vaccine"},{"key":"B46","doi-asserted-by":"publisher","first-page":"5861","DOI":"10.1038\/s41467-021-25982-w","article-title":"Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil","volume":"12","author":"Clemens","year":"2021","journal-title":"Nat Commun"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.2139\/ssrn.3822780","article-title":"Efficacy and safety of a COVID-19 inactivated vaccine in healthcare professionals in Brazil: The PROFISCOV study","author":"Palacios","year":"2021","journal-title":"EuropePMC"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(21)00677-0","article-title":"Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b\/3 trial","volume":"22","author":"Kremsner","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2116298","article-title":"Evaluation of the BNT162b2 covid-19 vaccine in children 5 to 11 years of age","volume":"386","author":"Walter","year":"2022","journal-title":"N Engl J Med"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, south Africa, and the UK","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"},{"key":"B51","volume-title":"BNT162b2 [Comirnaty (COVID-19 vaccine, mRNA)] evaluation of a booster dose (third dose) vaccines and related biological products advisory committee briefing document","year":"2022"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2116185","article-title":"Efficacy and safety of NVX-CoV2373 in adults in the united states and Mexico","volume":"386","author":"Dunkle","year":"2022","journal-title":"N Engl J Med"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)02753-7","article-title":"Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial","volume":"399","author":"Halperin","year":"2022","journal-title":"Lancet"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2115597","article-title":"Phase 3 trial of mRNA-1273 during the delta-variant surge","volume":"385","author":"Baden","year":"2021","journal-title":"N Engl J Med"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00055-1","article-title":"Efficacy of the adjuvanted subunit protein COVID-19 vaccine, SCB-2019: a phase 2 and 3 multicentre, double-blind, randomised, placebo-controlled trial","volume":"399","author":"Bravo","year":"2022","journal-title":"Lancet"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2117608","article-title":"Final analysis of efficacy and safety of single-dose Ad26.COV2.S","volume":"386","author":"Sadoff","year":"2022","journal-title":"N Engl J Med"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2103055","article-title":"Efficacy of NVX-CoV2373 covid-19 vaccine against the B.1.351 variant","volume":"384","author":"Shinde","year":"2021","journal-title":"N Engl J Med"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1101\/2022.03.22.22272769","article-title":"Vaccine effectiveness of two and three doses of BNT162b2 and CoronaVac against COVID-19 in Hong Kong","author":"McMenamin","year":"2022","journal-title":"medRxiv"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2021.12.046","article-title":"Efficacy and safety of the BNT162b2 mRNA COVID-19 vaccine in participants with a history of cancer: subgroup analysis of a global phase 3 randomized clinical trial","volume":"40","author":"Thomas","year":"2022","journal-title":"Vaccine"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7109e3","article-title":"Effectiveness of COVID-19 pfizer-BioNTech BNT162b2 mRNA vaccination in preventing COVID-19-Associated emergency department and urgent care encounters and hospitalizations among nonimmunocompromised children and adolescents aged 5-17 years - VISION network, 10 states, April 2021-January 2022","volume":"71","author":"Klein","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(21)00680-0","article-title":"Effectiveness of ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 infection during the delta (B.1.617.2) variant surge in India: a test-negative, case-control study and a mechanistic study of post-vaccination immune responses","volume":"22","author":"Thiruvengadam","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2119270","article-title":"Effectiveness of BNT162b2 vaccine against omicron variant in south Africa","volume":"386","author":"Collie","year":"2022","journal-title":"N Engl J Med"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01583-4","article-title":"BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 delta variant in Qatar","volume":"27","author":"Tang","year":"2021","journal-title":"Nat Med"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2021.1969291","article-title":"Effectiveness of inactivated SARS-CoV-2 vaccines against the delta variant infection in guangzhou: a test-negative case-control real-world study","volume":"10","author":"Li","year":"2021","journal-title":"Emerg Microbes Infect"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1101\/2021.12.20.21267966","article-title":"Vaccine effectiveness against SARS-CoV-2 infection with the omicron or delta variants following a two-dose or booster BNT162b2 or mRNA-1273 vaccination series: a Danish cohort study","author":"Hansen","year":"2021","journal-title":"medRxiv"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2108891","article-title":"Effectiveness of covid-19 vaccines against the B.1.617.2 (Delta) variant","volume":"385","author":"Lopez Bernal","year":"2021","journal-title":"N Engl J Med"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2021-068848","article-title":"Effectiveness of mRNA-1273 against delta, mu, and other emerging variants of SARS-CoV-2: test negative case-control study","volume":"375","author":"Bruxvoort","year":"2021","journal-title":"Bmj"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1101\/2022.02.25.22271454","article-title":"Effectiveness of the BNT162b2 vaccine among children 5-11 and 12-17 years in new York after the emergence of the omicron variant","author":"Dorabawila","year":"2022","journal-title":"MedRxiv"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2114089","article-title":"Effectiveness of the mRNA-1273 vaccine during a SARS-CoV-2 delta outbreak in a prison","volume":"385","author":"Chin","year":"2021","journal-title":"N Engl J Med"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1101\/2022.02.26.22271509","article-title":"Effect of booster vaccination against delta and omicron variants in Iceland","author":"Norddahl","year":"2022","journal-title":"medRxiv"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2021-069761","article-title":"Clinical severity of, and effectiveness of mRNA vaccines against, covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the united states: prospective observational study","volume":"376","author":"Lauring","year":"2022","journal-title":"BMJ"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1101\/2022.02.01.22270232","article-title":"Protection by 4th dose of BNT162b2 against omicron in Israel","author":"Bar-On","year":"2022","journal-title":"medRxiv"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1038\/s41564-021-01053-0","article-title":"Effectiveness of COVID-19 vaccines against symptomatic SARS-CoV-2 infection and severe outcomes with variants of concern in Ontario","volume":"7","author":"Nasreen","year":"2022","journal-title":"Nat Microbiol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1101\/2022.02.06.22270457","article-title":"Protection of COVID-19 vaccination and previous infection against omicron BA.1 and delta SARS-CoV-2 infections, the Netherlands, 22 November 2021- 19 January 2022","author":"Andeweg","year":"2022","journal-title":"medRxiv"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1101\/2021.12.28.21268436","article-title":"Vaccine effectiveness against hospital admission in south African health care workers who received a homologous booster of Ad26.COV2 during an omicron COVID19 wave: Preliminary results of the sisonke 2 study","author":"Gray","year":"2021","journal-title":"medRxiv"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1101\/2022.02.04.22270480","article-title":"SARS-CoV-2 omicron symptomatic infections in previously infected or vaccinated south African healthcare workers","author":"Nunes","year":"2022","journal-title":"medRxiv"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2021-069052","article-title":"Effectiveness of mRNA vaccines and waning of protection against SARS-CoV-2 infection and severe covid-19 during predominant circulation of the delta variant in Italy: retrospective cohort study","volume":"376","author":"Fabiani","year":"2022","journal-title":"BMJ"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7034e4","article-title":"Effectiveness of COVID-19 vaccines in preventing SARS-CoV-2 infection among frontline workers before and during B.1.617.2 (Delta) variant predominance - eight U.S. locations, December 2020-august 2021","volume":"70","author":"Fowlkes","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)02183-8","article-title":"Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study","volume":"398","author":"Tartof","year":"2021","journal-title":"Lancet"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2022.2037398","article-title":"Comparing real-life effectiveness of various COVID-19 vaccine regimens during the delta variant-dominant pandemic: A test-negative case-control study","volume":"11","author":"Sritipsukho","year":"2022","journal-title":"Emerg Microbes Infect"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01358-1","article-title":"SARS-CoV-2 delta VOC in Scotland: Demographics, risk of hospital admission, and vaccine effectiveness","volume":"397","author":"Sheikh","year":"2021","journal-title":"Lancet"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.7326\/M21-3509","article-title":"Effectiveness of inactivated COVID-19 vaccines against illness caused by the B.1.617.2 (Delta) variant during an outbreak in guangdong, China: A cohort study","volume":"175","author":"Kang","year":"2022","journal-title":"Ann Intern Med"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2021.26.35.2100793","article-title":"Vaccine effectiveness against infection with the delta (B.1.617.2) variant, Norway, April to august 2021","volume":"26","author":"Sepp\u00e4l\u00e4","year":"2022","journal-title":"Euro Surveill"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01548-7","article-title":"Effect of delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK","volume":"27","author":"Pouwels","year":"2021","journal-title":"Nat Med"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7034e3","article-title":"Effectiveness of pfizer-BioNTech and moderna vaccines in preventing SARS-CoV-2 infection among nursing home residents before and during widespread circulation of the SARS-CoV-2 B.1.617.2 (Delta) variant - national healthcare safety network, march 1-august 1, 2021","volume":"70","author":"Nanduri","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.23641","article-title":"Association of a third dose of BNT162b2 vaccine with incidence of SARS-CoV-2 infection among health care workers in Israel","volume":"327","author":"Spitzer","year":"2022","journal-title":"Jama"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7104e3","article-title":"Effectiveness of a third dose of mRNA vaccines against COVID-19-Associated emergency department and urgent care encounters and hospitalizations among adults during periods of delta and omicron variant predominance - VISION network, 10 states, august 2021-January 2022","volume":"71","author":"Thompson","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiab556","article-title":"Effectiveness of a third dose of BNT162b2 mRNA vaccine","volume":"225","author":"Saciuk","year":"2022","journal-title":"J Infect Dis"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)02249-2","article-title":"Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study","volume":"398","author":"Barda","year":"2021","journal-title":"Lancet"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2021.100249","article-title":"Effectiveness of heterologous ChAdOx1 nCoV-19 and mRNA prime-boost vaccination against symptomatic covid-19 infection in Sweden: A nationwide cohort study","volume":"11","author":"Nordstr\u00f6m","year":"2021","journal-title":"Lancet Reg Health Eur"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7104a2","article-title":"Effectiveness of a third dose of pfizer-BioNTech and moderna vaccines in preventing COVID-19 hospitalization among immunocompetent and immunocompromised adults - united states, august-December 2021","volume":"71","author":"Tenforde","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.1922","article-title":"Association of homologous and heterologous vaccine boosters with COVID-19 incidence and severity in Singapore","volume":"327","author":"Tan","year":"2022","journal-title":"JAMA"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1101\/2022.01.25.22269804","article-title":"Comparison of vaccine effectiveness against the omicron (B.1.1.529) variant in patients receiving haemodialysis","author":"Spensley","year":"2022","journal-title":"medRxiv"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1101\/2022.02.24.22271347","article-title":"Booster protection against omicron infection in a highly vaccinated cohort","author":"Tai","year":"2022","journal-title":"medRxiv"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2021.26.39.2100894","article-title":"Product-specific COVID-19 vaccine effectiveness against secondary infection in close contacts, navarre, Spain, April to august 2021","volume":"26","author":"Mart\u00ednez-Baz","year":"2021","journal-title":"Euro Surveill"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2021.12.032","article-title":"Cohort study of covid-19 vaccine effectiveness among healthcare workers in Finland, December 2020\u2013October 2021","volume":"40","author":"Poukka","year":"2022","journal-title":"Vaccine"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1101\/2021.10.26.21265397","article-title":"Two-dose SARS-CoV-2 vaccine effectiveness with mixed schedules and extended dosing intervals: test-negative design studies from British Columbia and Quebec, Canada","author":"Skowronski","year":"2021","journal-title":"medRxiv"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2114290","article-title":"Effectiveness of BNT162b2 vaccine against delta variant in adolescents","volume":"385","author":"Reis","year":"2021","journal-title":"N Engl J Med"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1101\/2021.09.15.21263583","article-title":"Vaccine effectiveness and duration of protection of comirnaty, vaxzevria and spikevax against mild and severe COVID-19 in the UK","author":"Andrews","year":"2021","journal-title":"medRxiv"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2114228","article-title":"Waning immunity after the BNT162b2 vaccine in Israel","volume":"385","author":"Goldberg","year":"2021","journal-title":"New Engl J Med"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1101\/2022.03.27.22273000","article-title":"Nationwide effectiveness of first and second SARS-CoV2 booster vaccines during the delta and omicron pandemic waves in Hungary (HUN-VE 2 study)","author":"Kiss","year":"2022","journal-title":"medRxiv"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1101\/2022.03.29.22273086","article-title":"Age and product dependent vaccine effectiveness against SARS-CoV-2 infection and hospitalisation among adults in Norway: A national cohort study, July - November 2021","author":"Starrfelt","year":"2022","journal-title":"medRxiv"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1101\/2022.03.24.22272854","article-title":"Vaccine effectiveness with BNT162b2 (Comirnaty, pfizer-BioNTech) vaccine against reported SARS-CoV-2 delta and omicron infection among adolescents, Norway, august 2021 to January 2022","author":"Veneti","year":"2022","journal-title":"medRxiv"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1101\/2022.03.22.22272691","article-title":"COVID-19 vaccine effectiveness against the omicron BA.2 variant in England","author":"Kirsebom","year":"2022","journal-title":"medRxiv"},{"key":"B105","doi-asserted-by":"publisher","first-page":"6379","DOI":"10.1038\/s41467-021-26672-3","article-title":"Correlation of SARS-CoV-2-breakthrough infections to time-from-vaccine","volume":"12","author":"Mizrahi","year":"2021","journal-title":"Nat Commun"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2021-067873","article-title":"Elapsed time since BNT162b2 vaccine and risk of SARS-CoV-2 infection: test negative design study","volume":"375","author":"Israel","year":"2021","journal-title":"BMJ"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2116063","article-title":"Covid-19 vaccine effectiveness in new York state","volume":"386","author":"Rosenberg","year":"2022","journal-title":"N Engl J Med"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N Engl J Med"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1101\/2022.04.11.22273327","article-title":"Effectiveness of the BNT162b vaccine fourth dose in reducing SARS-CoV-2 infection among healthcare workers in Israel, a multi-center cohort study","author":"Cohen","year":"2022","journal-title":"medRxiv"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7111e1","article-title":"Effectiveness of 2-dose BNT162b2 (Pfizer BioNTech) mRNA vaccine in preventing SARS-CoV-2 infection among children aged 5-11 years and adolescents aged 12-15 years - PROTECT cohort, July 2021-February 2022","volume":"71","author":"Fowlkes","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1101\/2022.04.07.22273319","article-title":"Vaccine effectiveness of BNT162b2 against omicron and delta outcomes in adolescents","author":"Buchan","year":"2022","journal-title":"medRxiv"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1101\/2022.02.07.22270568","article-title":"Duration of protection of BNT162b2 and mRNA-1273 COVID-19 vaccines against symptomatic SARS-CoV-2 omicron infection in Qatar","author":"Chemaitelly","year":"2022","journal-title":"medRxiv"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1101\/2022.03.30.22273193","article-title":"Effectiveness of an inactivated covid-19 vaccine with homologous and heterologous boosters against the omicron (B.1.1.529) variant","author":"Ranzani","year":"2022","journal-title":"medRxiv"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1101\/2022.03.11.22272140","article-title":"High vaccine effectiveness against severe covid-19 in the elderly in Finland before and after the emergence of omicron","author":"Baum","year":"2022","journal-title":"medRxiv"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(22)00101-1","article-title":"Durability of BNT162b2 vaccine against hospital and emergency department admissions due to the omicron and delta variants in a large health system in the USA: A test-negative case-control study","volume":"10","author":"Tartof","year":"2022","journal-title":"Lancet Respir Med"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1101\/2022.04.01.22273281","article-title":"Effectiveness of COVID-19 vaccines against omicron and delta hospitalisation: Test negative case-control study","author":"Stowe","year":"2022","journal-title":"medRxiv"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1101\/2022.02.25.22271494","article-title":"Waning effectiveness of the third dose of the BNT162b2 mRNA COVID-19 vaccine","author":"Patalon","year":"2022","journal-title":"medRxiv"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"B121","volume-title":"An international randomised trial of candidate vaccines against COVID-19","year":"2021"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1080\/03610929808832160","article-title":"Exact power and sample size for vaccine efficacy studies","volume":"27","author":"Chan","year":"1998","journal-title":"Commun Stat Theory Methods"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"B124","article-title":"Statistical methods in cancer research. volume II\u2013the design and analysis of cohort studies","volume":"87","author":"Breslow","year":"1987","journal-title":"IARC Sci Publ"},{"key":"B125","volume-title":"Epidemiologic research: principles and quantitative methods","author":"Kleinbaum","year":"1982"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.2307\/2533446","article-title":"Operating characteristics of a rank correlation test for publication bias","volume":"50","author":"Begg","year":"1994","journal-title":"Biometrics"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"Br Med J"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(21)00681-2","article-title":"Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials","volume":"22","author":"Zeng","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)02717-3","article-title":"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial","volume":"398","author":"Munro","year":"2021","journal-title":"Lancet"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1101\/2021.12.20.21268130","article-title":"High rate of asymptomatic carriage associated with variant strain omicron","author":"Garrett","year":"2022","journal-title":"medRxiv"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jpclett.2c00912","article-title":"Immune escape mechanisms of SARS-CoV-2 delta and omicron variants against two monoclonal antibodies that received emergency use authorization","volume":"27","author":"Xiong","year":"2022","journal-title":"J Phys Chem Lett"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1101\/2021.12.08.21267417v3","article-title":"SARS-CoV-2 omicron has extensive but incomplete escape of pfizer BNT162b2 elicited neutralization and requires ACE2 for infection","author":"Cele","year":"2021","journal-title":"medRxiv"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1101\/2021.12.07.21267432v4","article-title":"Reduced neutralization of SARS- CoV-2 omicron variant by vaccine sera and monoclonal antibodies","author":"Wilhelm","year":"2021","journal-title":"medRxiv"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2021.12.046","article-title":"Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses","volume":"185","author":"Dejnirattisai","year":"2022","journal-title":"Cell"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00094-0","article-title":"Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study","volume":"399","author":"Costa Clemens","year":"2022","journal-title":"Lancet"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01704-7","article-title":"Neutralizing antibodies against the SARS-CoV-2 omicron variant BA.1 following homologous and heterologous CoronaVac or BNT162b2 vaccination","volume":"28","author":"Cheng","year":"2022","journal-title":"Nat Med"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab1041","article-title":"Neutralization of severe acute respiratory syndrome coronavirus 2 omicron variant by sera from BNT162b2 or CoronaVac vaccine recipients","author":"Lu","year":"2021","journal-title":"Clin Infect Dis"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01705-6","article-title":"Neutralizing antibodies against the SARS-CoV-2 delta and omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination","volume":"28","author":"P\u00e9rez-Then","year":"2022","journal-title":"Nat Med"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp2002125","article-title":"Defining the epidemiology of Covid-19\u2013studies needed","volume":"382","author":"Lipsitch","year":"2020","journal-title":"N Engl J Med"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2109229118","article-title":"Asymptomatic SARS-CoV-2 infection: A systematic review and meta-analysis","volume":"118","author":"Sah","year":"2021","journal-title":"Proc Natl Acad Sci USA"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2109072","article-title":"Covid-19 breakthrough infections in vaccinated health care workers","volume":"385","author":"Bergwerk","year":"2021","journal-title":"N Engl J Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.945930\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,26]],"date-time":"2022-08-26T07:30:56Z","timestamp":1661499056000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.945930\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,26]]},"references-count":141,"alternative-id":["10.3389\/fimmu.2022.945930"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.945930","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,26]]},"article-number":"945930"}}